At 7.9% CAGR, the Asia Pacific Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is Projected to be Worth US$ 400.9 million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market was valued at US$ 217.6 million in 2022 and is expected to reach US$ 400.9 million by 2030, registering a CAGR of 7.9% from 2022 to 2030. Technological advancements in fluorescence in situ hybridization imaging and increasing R&D investments in in-vitro diagnostics attributed to the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market expansion.   

FISH imaging systems are witnessing a remarkable evolution due to the surge in technological advancements, which result in cutting-edge innovations transforming the landscape of genetic research and diagnostics. These advancements include enhanced optics, more sensitive and versatile fluorophores, and sophisticated automation features. Modern FISH imaging systems, integrated with these upgraded features, offer greater sensitivity, improved image resolution, and faster processing times. Moreover, these technological advancements have extended the application scope of FISH imaging from cancer diagnosis to genetic predisposition testing. In July 2021, BioView and Capio Biosciences collaborated to create a platform for collecting circulating tumor cells (CTCs) from whole blood. By integrating their technologies, these companies further worked on improving the CTC liquid biopsy downstream analysis. Similarly, BioView and Capio Biosciences, in collaboration, partnered with RUBYnanomed in December 2020 to create a unique imaging solution to accelerate the acceptance and adoption of CTC technology in clinics to enhance cancer detection. Thus, technological advancements in FISH imaging systems create significant opportunities for companies in the fluorescence in situ hybridization (FISH) imaging systems market.

On the contrary, high cost of fish imaging systems and procedures hamper the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market.

Based on product, the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market is segmented into instruments, consumables, accessories, and software. The consumables held 56.6% share of Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 110.3 million. It is projected to garner US$ 206.2 million by 2030 to expand at 8.1% CAGR during 2022–2030.

In terms of application, the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnostic, and others. The cancer diagnosis segment held 66.8% share of Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 105.1 million. It is projected to garner US$ 198.2 million by 2030 to expand at 8.3% CAGR during 2022–2030.

Based on end users, the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held 75.8% share of Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 164.9 million. It is projected to garner US$ 305.7 million by 2030 to expand at 8.0% CAGR during 2022–2030.

By country, the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market has been categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 35.3% share of Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market in 2022. It was assessed at US$ 76.75 million in 2022 and is likely to hit US$ 148.47 million by 2030, exhibiting a CAGR of 8.6% during 2022–2030.  

Key players operating the Asia Pacific fluorescence in-situ hybridization (FISH) imaging systems market Euroclone SpA, Tissuegnostics Gmbh, Agilent Technologies Inc, Abnova Taiwan Corp, Biogenex Laboratories Inc, Leica Biosystems Nussloch Gmbh, Metasystems Probes Gmbh, Bio-View Ltd, And Thermo Fisher Scientific Inc, among others.

• Thermo Fisher Scientific Inc, May-2023, Collaboration Pfizer and Thermo Fisher Scientific Inc entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia where advanced genomic testing was previously limited or unavailable. Access to local NGS testing can help enable faster analysis of related genes, allowing healthcare providers to choose the best medicine for that specific patient.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com